Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
patients' quality of life
1
The outcome of a post-hoc analysis of the phase 2b study published in the Journal of the European Academy of Dermatology and Venerology provides new possibilities for patients struggling with uncontrolled atopic dermatitis
Clinical trial subjects treated with nemolizumab demonstrated significant itch relief as early as 48 hours after treatment
that persisted throughout the duration of the study (up to week 16)
2
Subjects treated with nemolizumab reported significant sleep improvements as early as 72 hours after the first injection which were sustained, and improved further throughout the duration of the trial (up to week 16)